Table 1.
Patient’s characteristics and clinical data comparing the two study groups
| Characteristics | 1 g/8 h group (N = 16) | 2 g/8 h group (N = 15) | P value |
|---|---|---|---|
| Demographic and clinical data | |||
| Male, n (%) | 12 (75) | 13 (86.7) | 0.654 |
| Age (years) | 64.0 (20.0) | 75.0 (14.0) | 0.202 |
| Body weight (kg) | 74.0 (14.8) | 70.0 (15.0) | 0.495 |
| BMI (kg/m2) | 26.8 (3.8) | 25.5 (6.4) | 0.338 |
| Charlson Comorbidity Index | 4.0 (3.5) | 6.0 (4.0) | 0.033 |
| APACHE II scorea | 13.0 (10.8) | 15.0 (6.0) | 0.423 |
| Other clinical datab | |||
| Type of pneumonia, n (%) | > 0.999 | ||
| Ventilator-associated pneumonia | 4 (25) | 4 (26.7) | |
| Hospital-acquired pneumonia | 12 (75) | 11 (73.3) | |
| SOFA score | 5 (4) | 5 (5) | 0.830 |
| Septic shock, n (%) | 4 (25) | 3 (20) | > 0.999 |
| Sepsis, n (%) | 10 (62.5) | 12 (80) | 0.433 |
| Concomitant bacteremia, n (%) | 3 (18.8) | 2 (13.3) | > 0.999 |
| Fluid overload, n (%) | 2 (12.5) | 6 (40) | 0.113 |
| Mechanical ventilation, n (%) | 4 (25) | 4 (26.7) | > 0.999 |
| GFR (mL/min/1.73 m2) | 103.0 (33.0) | 85.0 (30.0) | 0.281 |
| GFR < 90 mL/min/1.73 m2, n (%) | 6 (37.5) | 9 (60.0) | 0.210 |
| GFR > 120 mL/min/1.73 m2, n (%) | 2 (12.5) | 3 (13.3) | > 0.999 |
| C-reactive protein (mg/dL) | 15.0 (26.9) | 17.5 (14.1) | 0.654 |
| Procalcitonin (ng/mL) | 0.8 (2.1) | 0.9 (3.6) | 0.375 |
| Total serum protein (g/dL) | 5.2 (1.4) | 5.1 (1.0) | 0.830 |
| Serum albumin (g/dL) | 2.9 (0.9) | 2.8 (0.6) | 0.599 |
| Clinical and microbiological outcomes | |||
| Clinical cure, n (%) | 13 (81.3) | 11 (73.3) | 0.685 |
| Length of ICU stay (days) | 19.9 (15.8) | 18.2 (17.4) | 0.730 |
| Length of hospital stay (days) | 39.5 (54.8) | 28.0 (55.0) | 0.682 |
| Microbiological eradication, n (%) | 4 (25.0%) | 7 (46.7%) | 0.494 |
| Seven-day all-cause mortality, n (%) | 0 (0) | 0 (0) | > 0.999 |
| Thirty-day all-cause mortality, n (%) | 1 (6.3) | 1 (6.7) | > 0.999 |
| In-hospital mortality, n (%) | 1 (6.3) | 1 (6.7) | > 0.999 |
| Microbiological data: specie, n (%)/MIC (mg/L)c | |||
| Gram-negative bacteria | 6 (37.5) | 7 (46.7) | 0.605 |
| MDR Gram-negative bacteria | 3 (18.8) | 2 (13.3) | > 0.999 |
| Pseudomonas aeruginosa (PA) | 3 (18.8) | 2 (13.3) | > 0.999 |
| Multi-susceptible PA | 2 (12.5)/≤ 2 | 0 (0) | 0.484 |
| MDR PA | 0 (0) | 1 (6.7)/16 | 0.484 |
| XDR PA | 1 (6.3)/8 | 1 (6.7)/32 | > 0.999 |
| Enterobacteriaceae | 3 (18.8) | 3 (20.0) | > 0.999 |
| ESBL producers | 3 (18.8) / ≤2 | 0 (0) | 0.226 |
| Other Gram-negative bacteria | 1 (6.3)/≤ 2 | 3 (20.0)/≤2 | 0.333 |
MDR multidrug-resistant, XDR extensively drug-resistant, ESBL extended-spectrum beta-lactamases
aCalculated at the beginning of ICU admission
bData at the onset of treatment
cBased on EUCAST breakpoints